Mode
Text Size
Log in / Sign up

Secukinumab improves cutaneous adipose tissue inflammatory signatures in psoriasis patientsFat Under Your Skin Fuels Psoriasis Inflammation

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that secukinumab improves cutaneous adipose tissue inflammatory signatures, with greater effects in obese patients.

This randomized placebo-controlled trial investigated the effects of secukinumab on the cutaneous adipose tissue (CAT) transcriptome in patients with psoriasis. The study population consisted of 82 participants, comparing secukinumab treatment against placebo. Primary assessments focused on gene expression profiles and inflammatory pathways within lesional and non-lesional skin-associated adipose tissue.

Analysis of differentially expressed transcripts revealed that psoriatic CAT exhibited 2132 differentially expressed transcripts compared with healthy controls. Obese psoriatic CAT demonstrated a more than 2-fold higher number of differentially expressed genes than non-obese counterparts. Treatment with secukinumab markedly improved inflammatory signatures in psoriatic CAT. Notably, greater improvements in these inflammatory signatures were observed in obese patients relative to non-obese patients.

Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported in the study. Specific p-values or confidence intervals for the primary outcomes were not provided in the available data. The study did not report specific limitations, funding sources, or conflicts of interest. While the results highlight a biological effect of secukinumab on CAT inflammation, the absence of reported safety data and specific statistical measures limits the ability to fully assess clinical risk-benefit profiles. The findings are specific to transcriptomic changes and do not directly translate to standard clinical efficacy metrics like PASI scores.

The Hidden Fire Under Your Skin

Imagine looking at a patch of red, scaly skin on your arm. You see the problem right there. But what if the real trouble is happening just beneath the surface?

For years, doctors thought psoriasis was only a skin disease. It happens on the outside. But new research shows that the fat under your skin is part of the problem too.

This fat is called cutaneous adipose tissue. It sits right under your skin. In people with psoriasis, this fat is not quiet. It is shouting. It is releasing chemicals that make the skin flare up.

Psoriasis affects millions of people worldwide. It causes pain, itching, and embarrassment. Many patients feel self-conscious about their skin.

But the struggle goes deeper. Many people also have obesity. Doctors have long wondered if these two conditions are linked. Did the skin cause the weight gain? Or did the weight cause the skin issues?

This study answers that question. It shows that the fat under the skin in obese patients is much more inflamed. This creates a vicious cycle. The skin gets worse, the body gets heavier, and the fat gets more angry.

The Surprising Shift

Scientists used to think the skin was the only place where this disease lived. They looked at the red patches and stopped there. They missed the bigger picture.

But here is the twist. The study looked at fat from two areas. One area had the red skin patches. The other area looked normal.

You would expect the normal skin to be fine. But it was not. The fat under the normal skin was also inflamed. This means the disease is not just in the red spots. It is spreading through your body fat.

Think of your immune system like a security team. In a healthy body, they stay calm unless there is a threat. In psoriasis, the security team goes into overdrive.

They release signals called cytokines. These signals tell cells to attack. In this study, scientists found a specific signal called IL-17. This signal is like a loud alarm bell.

When this bell rings, it tells the fat cells to get angry. They start releasing their own inflammatory chemicals. This is like a fire that starts in the basement and spreads to the whole house.

Researchers studied 82 patients with psoriasis. They took small samples of fat from under the skin. They compared these samples to fat from healthy people.

They also tested a drug called secukinumab. This drug blocks the IL-17 alarm bell. The study lasted a specific time to see how the body reacted to the treatment.

The results were clear. The fat in psoriasis patients was very different from healthy fat. There were over 2,000 genes working differently in the diseased fat.

This means the cells were behaving strangely. They were ready to fight, even without a real enemy. This constant fighting causes the pain and the redness.

The study also looked at weight. Patients who were obese had double the number of these strange genes. This proves that extra weight makes the skin disease much worse.

But there is a catch. The good news is that the drug worked. When patients took secukinumab, the inflammation in the fat went down. The alarm bell stopped ringing.

Interestingly, the drug worked even better in obese patients. This is surprising. Usually, harder-to-treat cases are the hardest to fix. But here, blocking the specific signal helped the most in the heaviest patients.

Doctors are excited about this finding. It changes how they view the disease. Psoriasis is not just a skin issue. It is a whole-body issue involving your fat.

This helps explain why some patients struggle more than others. It also suggests that losing weight could help, but it might not be enough. The specific signal must be blocked too.

If you have psoriasis, know that your body fat is part of the story. Do not blame yourself for the condition. Your biology is complex.

This treatment is not available yet. It is still in the research phase. You cannot buy secukinumab just for this reason. You need a prescription for your specific skin condition.

Talk to your doctor about your weight and your skin. Managing your weight is always good for your health. But you also need the right skin treatment.

This study is important, but it has limits. It only looked at 82 people. That is a small number for such a big disease.

Also, the study was short. We do not know if the benefits last for years. We also do not know if this works for everyone.

Scientists will now test this in larger groups. They want to see if this approach works for many people. They also want to know if blocking this signal helps other diseases.

It may take years for a new drug to reach the pharmacy. The process is slow and careful. Safety comes first.

For now, the message is clear. Your skin and your fat are connected. Understanding this link is the first step toward better care.

Study Details

Study typeRct
Sample sizen = 82
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
This study provides a comprehensive evaluation of the cutaneous adipose tissue (CAT) transcriptome in patients with psoriasis and investigates the effects of IL-17 blockade on CAT inflammation through a randomized placebo-controlled trial using secukinumab (ObePso-S study, ClinicalTrials.gov NCT03055494). RNA sequencing analysis of CAT biopsies from 82 patients with psoriasis revealed 2132 differentially expressed transcripts compared with healthy controls. Notably, significant gene dysregulation was observed in both lesional skin (LS)-CAT and non-lesional (NL)-CAT, including activation of IL-17-driven pathways, antimicrobial peptide-related, and neutrophil degranulation signatures. Stratification by obesity demonstrated that obese psoriatic CAT exhibited a more than 2-fold higher number of differentially expressed genes than non-obese counterparts, suggesting a synergistic interaction between psoriasis and obesity in driving CAT inflammation. Treatment with secukinumab markedly improved inflammatory signatures in psoriatic CAT, with greater improvements observed in obese patients. These findings reveal a pronounced and partially IL-17-dependent inflammatory phenotype in psoriatic CAT, challenge the conventional concept of psoriasis as a solely superficial skin disease, and highlight CAT as an important contributor to systemic inflammation in psoriasis.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.